RadioNano Therapeutics is a Kyoto University spinout developing next-gration nanomedicines for Boron Neutron Capture Therapy (BNCT). Its lead program, RN-501, is designed to overcome key limitations of current BNCT agents through superior tumor accumulation and retention, enabling the treatment of deep-seated, recurrent, metastatic, and diffuse cancers that remain challenging to address with existing therapies.
Built on world-leading expertise in BNCT and nanotechnology, RadioNano Therapeutics is advancing a novel precision radiotherapy platform with the potential to expand the clinical utility of BNCT beyond its current applications. The company is progressing RN-501 toward clinical development and global commercialization to address significant unmet medical needs and unlock substantial opportunities across large oncology markets, with the goal of improving outcomes for patients with difficult-to-treat cancers worldwide.
Hiuchi Pharma is a biotechnology company developing first-in-class therapeutics targeting TRPC3/C6 channels for pulmonary arterial hypertension (PAH) and other cardiovascular and renal diseases. Its lead program, L862, is an orally available small molecule designed to inhibit pathological vascular remodeling, a fundamental driver of disease progression that remains inadequately addressed by current therapies. Built on pioneering research that established the critical role of TRPC3/C6 in cardiovascular remodeling, Hiuchi Pharma is advancing a novel disease-modifying approach for patients with serious and life-threatening chronic conditions. Beyond PAH, the company sees broad potential for TRPC3/C6-targeted therapies across multiple indications, including heart failure and kidney diseases. Through its innovative pipeline, Hiuchi Pharma aims to improve long-term outcomes while addressing significant unmet medical needs.
ANT5 is a medical technology company developing the world’s first multimodal brain monitoring platform for patients with severe brain injury. Its proprietary system integrates EEG, intracranial pressure, cerebral oxygenation, blood flow, and brain temperature monitoring into a single device, enabling continuous real-time assessment of brain status and early detection of secondary brain injury. Built on decades of neuroscience and neurocritical care research, ANT5 is addressing a critical unmet need in the management of traumatic brain injury, stroke, and other acute neurological conditions, where timely intervention can significantly impact patient outcomes. Through advanced monitoring technologies and future AI-driven analytics, the company aims to support clinical decision-making, improve neurological recovery, and establish a new standard of care in neurocritical medicine worldwide.
Juntendo University is developing a first-in-class in vivo direct reprogramming gene therapy for Type 1 Diabetes, with the goal of replacing lifelong insulin dependence through a single disease-modifying treatment.Its proprietary OKAP platform utilizes patented K-Factor technology to directly convert liver cells into functional insulin-producing cells in vivo, eliminating the need for cell transplantation. Delivered through AAV- or LNP-based gene therapy, the approach is designed to restore physiological glucose regulation, reduce the burden of daily insulin management, and potentially achieve long-term insulin independence.Supported by compelling preclinical data, the platform has the potential to transform diabetes treatment and may be expanded to additional indications, including insulin-dependent Type 2 Diabetes and other diseases addressable through in vivo cellular reprogramming.
Cellford is a regenerative medicine company developing the Injectable Cell Scaffold (ICS), a novel platform designed to overcome one of the most significant limitations of cell therapy: poor cell retention and survival at the target site. The technology is initially being developed for patients with critical limb ischemia (CLI), a severe vascular disease that can lead to limb amputation and has limited treatment options. By enabling long-term retention of therapeutic cells and sustained release of angiogenic factors, ICS promotes robust blood vessel formation and enhanced tissue regeneration. Developed as a medical device compatible with culture-free autologous cell therapies, the platform offers a scalable and cost-effective approach to regenerative medicine. CellFold aims to improve outcomes for patients with ischemic diseases while expanding the potential of cell-based therapies across multiple clinical applications.
FELIQS is a clinical-stage ophthalmology company developing innovative therapies for retinal and corneal diseases with significant unmet medical needs. The company is advancing a diversified pipeline targeting conditions including retinopathy of prematurity (ROP), pterygium, and dry age-related macular degeneration (Dry AMD), addressing diseases that currently have limited or no effective treatment options.
Leveraging novel mechanisms targeting oxidative stress, fibrosis, and angiogenesis, FELIQS is developing patient-friendly therapies designed to reduce dependence on invasive procedures while improving long-term visual outcomes. Through its innovative ophthalmology pipeline, FELIQS aims to preserve vision, prevent blindness, and improve quality of life for patients worldwide.
United Immunity is a clinical-stage biotechnology company developing next-generation immunotherapies through its proprietary Myeloid Targeting Platform™. The company selectively delivers therapeutic payloads to macrophages and dendritic cells, enabling innovative approaches in oncology, autoimmune diseases, and fibrosis. Its pipeline includes a clinical-stage TLR7/8 agonist program (UI-102) and an in vivo CAR-macrophage platform, supported by strategic collaborations and strong non-dilutive funding.
VC Cell Therapy (VCCT) is a seed/growth-stage biotechnology company developing a portfolio of ex vivo and in vivo cell therapy solutions for ocular diseases. We are a proud member of the Kobe Eye Center Initiative, a consortium of organizations that unifies research, clinical practice, and patient care, for the benefit of patients suffering from ocular diseases. Under the guiding principle of “Total solutions for every patient”, we challenge ourselves to think of every possible way to improve the lives of visually impaired people.